| [1] |
Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and genetics of hepatocellular carcinoma[J]. Gastroenterology, 2023, 164(5): 766-782. DOI: 10.1053/j.gastro.2023.01.033.
|
| [2] |
Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review[J]. JAMA Surg, 2023, 158(4): 410-420. DOI: 10.1001/jamasurg.2022.7989.
|
| [3] |
Guan MC, Wang MD, Liu SY, et al. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside[J]. World J Gastrointest Oncol, 2021, 13(4): 197-215. DOI: 10.4251/wjgo.v13.i4.197.
|
| [4] |
|
| [5] |
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76(3): 681-693. DOI: 10.1016/j.jhep.2021.11.018.
|
| [6] |
Xing H, Zhang WG, Cescon M, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study[J]. HPB, 2020, 22(5): 677-689. DOI: 10.1016/j.hpb.2019.09.006.
|
| [7] |
Zhang H, Zhang W, Jiang L, et al. Recent advances in systemic therapy for hepatocellular carcinoma[J]. Biomark Res, 2022, 10(1): 3. DOI: 10.1186/s40364-021-00350-4.
|
| [8] |
Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(4): 203-222. DOI: 10.1038/s41575-022-00704-9.
|
| [9] |
Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements[J]. Liver Cancer, 2020, 9(3): 245-260. DOI: 10.1159/000507370.
|
| [10] |
Hatanaka T, Yata Y, Naganuma A, et al. Treatment strategy for intermediate-stage hepatocellular carcinoma: transarterial chemoembolization, systemic therapy, and conversion therapy[J]. Cancers, 2023, 15(6): 1798. DOI: 10.3390/cancers15061798.
|
| [11] |
Brown ZJ, Brock Hewitt D, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress[J]. Expert Opin Investig Drugs, 2022, 31(4): 379-391. DOI: 10.1080/13543784.2022.2008355.
|
| [12] |
Wang MD, Sun LY, Qian GJ, et al. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: a retrospective cohort study[J]. Int J Surg, 2022, 105: 106843. DOI: 10.1016/j.ijsu.2022.106843.
|
| [13] |
Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China[J]. JAMA Surg, 2019, 154(3): 209-217. DOI: 10.1001/jamasurg.2018.4334.
|
| [14] |
Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78(6): 1922-1965. DOI: 10.1097/HEP.0000000000000466.
|
| [15] |
Xie D, Shi J, Zhou J, et al. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective[J]. Clin Mol Hepatol, 2023, 29(2): 206-216. DOI: 10.3350/cmh.2022.0402.
|
| [16] |
Goh MJ, Sinn DH, Kim JM, et al. Clinical practice guideline and real-life practice in hepatocellular carcinoma: a Korean perspective[J]. Clin Mol Hepatol, 2023, 29(2): 197-205. DOI: 10.3350/cmh.2022.0404.
|
| [17] |
Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer[J]. Hepatology, 2015, 62(2): 440-451. DOI: 10.1002/hep.27745.
|
| [18] |
Oramas DM, Moran CA. Major pathologic response in patients treated for non-small cell carcinoma of the lung: is there a magic number in the histologic sections to be evaluated?[J]. Adv Anat Pathol, 2021, 28(2): 67-71. DOI: 10.1097/PAP.0000000000000292.
|
| [19] |
Deng H, Xiong S, Zhong R, et al. "Major pathologic response" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy[J]. Exp Hematol Oncol, 2023, 12(1): 40. DOI: 10.1186/s40164-023-00401-6.
|
| [20] |
Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985. DOI: 10.1056/NEJMoa2202170.
|
| [21] |
Hieken TJ, Nelson GD, Flotte TJ, et al. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial[J]. Nat Commun, 2024, 15(1): 1430. DOI: 10.1038/s41467-024-45798-8.
|
| [22] |
Dacic S, Travis W, Redman M, et al. International association for the study of lung cancer study of reproducibility in assessment of pathologic response in resected lung cancers after neoadjuvant therapy[J]. J Thorac Oncol, 2023, 18(10): 1290-1302. DOI: 10.1016/j.jtho.2023.07.017.
|
| [23] |
Pataer A, Weissferdt A, Vaporciyan AA, et al. Evaluation of pathologic response in lymph nodes of patients with lung cancer receiving neoadjuvant chemotherapy[J]. J Thorac Oncol, 2021, 16(8): 1289-1297. DOI: 10.1016/j.jtho.2021.03.029.
|
| [24] |
Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 219-229. DOI: 10.1016/S2468-1253(21)00385-X.
|
| [25] |
Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218. DOI: 10.1016/S2468-1253(21)00427-1.
|
| [26] |
Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial[J]. J Immunother Cancer, 2022, 10(4): e004656. DOI: 10.1136/jitc-2022-004656.
|
| [27] |
Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity[J]. Nat Cancer, 2021, 2(9): 891-903. DOI: 10.1038/s43018-021-00234-4.
|
| [28] |
Fang Y, Liu W, Tang Z, et al. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack[J]. Hepatology, 2023, 77(1): 109-123. DOI: 10.1002/hep.32348.
|
| [29] |
Hussain HK, Barr DC, Wald C. Imaging techniques for the diagnosis of hepatocellular carcinoma and the evaluation of response to treatment[J]. Semin Liver Dis, 2014, 34(4): 398-414. DOI: 10.1055/s-0034-1394140.
|
| [30] |
Yoneda N, Matsui O, Kobayashi S, et al. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma[J]. Jpn J Radiol, 2019, 37(3): 191-208. DOI: 10.1007/s11604-019-00817-3.
|
| [31] |
Garg T, Shrigiriwar A, Habibollahi P, et al. Intraarterial therapies for the management of hepatocellular carcinoma[J]. Cancers, 2022, 14(14): 3351. DOI: 10.3390/cancers14143351.
|
| [32] |
Cheng X, Sun P, Hu QG, et al. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses[J]. J Cancer Res Clin Oncol, 2014, 140(7): 1159-1170. DOI: 10.1007/s00432-014-1677-4.
|
| [33] |
Li C, Wang MD, Lu L, et al. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥10 cm): a multicenter propensity matching analysis[J]. Hepatol Int, 2019, 13(6): 736-747. DOI: 10.1007/s12072-019-09981-0.
|
| [34] |
Fang C, Luo R, Zhang Y, et al. Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A/B hepatocellular carcinoma beyond Milan criteria: a randomized clinical trial[J]. Front Oncol, 2023, 13: 1101162. DOI: 10.3389/fonc.2023.1101162.
|
| [35] |
Zhou WP, Lai ECH, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J]. Ann Surg, 2009, 249(2): 195-202. DOI: 10.1097/SLA.0b013e3181961c16.
|
| [36] |
Qi X, Liu L, Wang D, et al. Hepatic resection alone versus in combination with pre-and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Oncotarget, 2015, 6(34): 36838-36859. DOI: 10.18632/oncotarget.5426.
|
| [37] |
Wei W, Li S, Zhao R, et al. Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: a multi-center, phase 3, randomized, controlled clinical trial[J]. J Clin Oncol, 2023, 41(16_suppl): 4023. DOI: 10.1200/jco.2023.41.16_suppl.4023.
|
| [38] |
Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24): 2141-2151. DOI: 10.1200/JCO.18.02184.
|
| [39] |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. DOI: 10.1056/NEJMoa0708857.
|
| [40] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
|
| [41] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
|
| [42] |
Topalian SL, Forde PM, Emens LA, et al. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy[J]. Cancer Cell, 2023, 41(9): 1551-1566. DOI: 10.1016/j.ccell.2023.07.011.
|
| [43] |
Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease[J]. Cancer Discov, 2016, 6(12): 1382-1399. DOI: 10.1158/2159-8290.CD-16-0577.
|
| [44] |
Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma[J]. Nat Med, 2018, 24(11): 1655-1661. DOI: 10.1038/s41591-018-0198-0.
|
| [45] |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med, 2018, 378(21): 1976-1986. DOI: 10.1056/NEJMoa1716078.
|
| [46] |
Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer[J]. N Engl J Med, 2023, 389(6): 491-503. DOI: 10.1056/NEJMoa2302983.
|
| [47] |
Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6): 556-567. DOI: 10.1056/NEJMoa2112651.
|
| [48] |
Cheung TT, Wai-Hung Ho D, Lyu SX, et al. Multimodal integrative genomics and pathology analyses in neoadjuvant nivolumab treatment for intermediate and locally advanced hepatocellular carcinoma[J]. Liver Cancer, 2023, 13(1): 70-88. DOI: 10.1159/000531176.
|
| [49] |
Song T. A prospective, single-arm, phase Ⅱ clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence[J]. J Clin Oncol, 2023, 41(16_suppl):e16218. DOI: 10.1200/JCO.2023.41.16_suppl.e16218.
|
| [50] |
|